Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 21, 2007

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Leukemia

Interventions

BIOLOGICAL

therapeutic autologous lymphocytes

DRUG

cyclophosphamide

Trial Locations (1)

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER